Copy
 
 
 
 
 
 

The Top 5 New Additions to Dry Eye


Dry eye diagnosis and management are evolving at an incredible pace. Doctors and patients can benefit from the expansive market growth.  Let's take a look at what's new and what they have to offer. Here's our Top 5, in no particular order:

1.  Xiidra:  Unless you live under a rock, you've heard of Xiidra (lifitegrast, 5%, Shire plc).  It's the first and only medication indicated for both the signs and symptoms of dry eye disease.  The twice-daily dosed ophthalmic med made a big splash in the market for both doctors and patients.  The massive product launch can be credited for breathing life into dry eye for many practices.  
 
2.  Restasis Multidose (MDPF):  Restasis (cyclosporine ophthalmic emulsion, 0.05%, Allergan plc) remains "king of the hill" in terms of pharmaceutical management of dry eye. This year, Allergan released Restasis MDPF which provides the same preservative-free mediation in a multi-dose bottle.  Some patients have balked over the use of vials and asked for a more convenient bottled version.  Now, there are no more excuses for poor compliance.
 
3. Meibography: That's not new technology you may say... but, affordability is very new.  Congratulations to TearScience and Box Medical Solutions for making meibography in reach for almost any practice.  The LipiScan (TearScience) and the Meibox both offer quality images at a modest capital investment.  For doctors that need more than imaging alone, the Oculus Keratograph brings meibography and topography at a value.  Practices can no longer use the excuse of equipment expense for sitting on the sidelines.
 
4.  Partnerships: Everyone wins when we all work together.  The recent partnerships and acquisitions in the dry eye arena will benefit patients and practices.  We look forward to watching how Johnson and Johnson develops a focus on dry eye disease with their pending acquisition of TearScience.  
 
5.  Thinking Outside the Box:  When doctors think of dry eye, 9 times of 10 the treatment recommended is a drop.  TrueTear (Allergan plc) is anything but a drop.  The intranasal neurostimulation device brings natural tears to patient's eyes.  When doctors first see TrueTear, they're often skeptical that patients will really use it.  Nothing could be further from the truth.  Patients want relief and are, generally, willing to try what's new to the market.

Whitney Hauser, OD
Founder, DryEyeCoach.com 
Doctors and patients can benefit from the expansive market growth.
How to Build a Successful Dry Eye Clinic.
 
Subscribe for FREE on www.DryEyeCoach.com.
Copyright © DryEyeCoach.com, All rights reserved.

4728 Spottswood Ave. Ste. 249

Memphis TN 38117-4817



Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list